Phosphonamidates that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
WO2020257173A1
Method of treating the osteoarthritic joint
WO2020092117A2
Killing senescent cells and treating senescence-associated conditions using a bel inhibitor and an mcl-1 inhibitor
US2019382371A1
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US2019330250A1
Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
EP3788052A1
Acyl phosphonamidates and acyl benzylamines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US2019248837A1
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
WO2019183042A1
Autologous mitochondrial extraction and expansion
EP3548504A1
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
WO2019133904A1
Inhibitors of hsp90, pi3-kinase, proteasome, hdac, and p97 pathways for selective removal of senescent cells in the treatment of age related conditions
US2019151337A1
Technology to inhibit vascular changes that lead to vision loss in the eye
WO2019060297A1
Mitochondrial rejuvenation as a treatment for adverse age-related conditions and neurodegeneration
WO2019033122A1
Treatment of lung diseases using pharmaceutical agents that eliminate senescent cells
CA3072673A1
Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US2020199103A1
Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US2018000816A1
Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
WO2017223107A1
Genome modifying enzyme therapy for diseases modulated by senescent cells
CA3033850A1
Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use
US2020291050A1
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
WO2017008060A1
Compositions and methods for treating senescence-associated diseases and disorders
